Jenny Sprooten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8743463/publications.pdf

Version: 2024-02-01

		1163117	1474206
10	642	8	9
papers	citations	h-index	g-index
10	10	10	847
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncolmmunology, 2020, 9, 1703449.	4.6	156
2	Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncolmmunology, 2019, 8, 1638212.	4.6	125
3	Necroptosis in Immuno-Oncology and Cancer Immunotherapy. Cells, 2020, 9, 1823.	4.1	109
4	Type I interferons and dendritic cells in cancer immunotherapy. International Review of Cell and Molecular Biology, 2019, 348, 217-262.	3.2	81
5	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. Oncolmmunology, 2022, 11, .	4.6	54
6	Type I interferons and endoplasmic reticulum stress in health and disease. International Review of Cell and Molecular Biology, 2020, 350, 63-118.	3.2	53
7	Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. , 2021, 9, e003609.		24
8	Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. Genes and Immunity, 2021, 22, 108-119.	4.1	17
9	Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study. Cancers, 2021, 13, 6259.	3.7	17
10	A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. Oncolmmunology, 2022, 11, 2024692.	4.6	6